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Treating anemia in patients with 
chronic kidney disease
Anemia is a common complication of chronic kidney disease, 
and it is strongly predictive of complications and death from 
cardiovascular causes. Observational data indicate that 
correction of anemia is associated with improved outcomes, 
but the optimal target hemoglobin levels for patients with 
various stages of chronic kidney disease are unclear. Two recent 
clinical trials addressed this important question.
In the Cardiovascular Risk Reduction by Early Anemia 
Treatment with Epoetin Beta (CREATE) trial, Drüeke et al.1 
tested whether complete correction of anemia in patients with 
stage 3 or 4 chronic kidney disease improves cardiovascular 
outcomes as compared with partial correction of anemia. 
In the Correction of Hemoglobin and Outcomes in Renal 
Insuffi  ciency (CHOIR) trial, Singh et al.2 tested whether the use 
of erythropoietin to achieve a high hemoglobin level (13.5 g per 
deciliter) in patients with chronic kidney disease would decrease 
the risk of complications from cardiovascular causes and death, 
as compared with a lower hemoglobin level (11.3 g per deciliter).
In the CREATE trial, 603 patients with an estimated 
glomerular fi ltration rate of 15.0 to 35.0 ml per minute and 
mild to moderate anemia were randomized to subcutaneous 
erythropoietin for complete correction of the anemia or only 
aft er the hemoglobin level fell below 10.5 g per deciliter. Th e 
primary end point was a composite of eight cardiovascular 
events; secondary end points included left  ventricular mass 
index, quality-of-life scores, and the progression of chronic 
kidney disease. At the end of 3 years, complete correction of 
anemia did not aff ect the likelihood of cardiovascular events, 
and there was no signifi cant diff erence in the combined 
incidence of adverse events between the two groups; but 
hypertensive episodes and headaches were more prevalent in 
the group of patients randomized to erythropoietin.
In the CHOIR trial, 1,432 patients were randomly assigned 
to receive a dose of erythropoietin targeted to achieve a 
hemoglobin level of 13.5 g per deciliter or assigned to receive a 
dose targeted to achieve a level of 11.3 g per deciliter. Th e median 
study duration was 16 months, and the primary end point was 
a composite of death, myocardial infarction, hospitalization for 
congestive heart failure (without renal replacement therapy), 
and stroke. Th e trial showed 125 events in the high-hemoglobin 
group, as compared with 97 events in the low-hemoglobin 
group. Th us, the use of a target hemoglobin level of 13.5 g per 
deciliter was associated with increased risk and no incremental 
improvement in the quality of life.
In sum, neither of the two trials confi rmed the hypothesis that 
normalization of the hemoglobin level would be benefi cial to 
patients with chronic kidney disease and warn to caution when 
correcting anemia in these patients. (1N Engl J Med 2006; 355: 
2071–2084. 2N Engl J Med 2006; 355: 2085–2098)
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Hyponatremia correction with 
an oral vasopressin V2-receptor 
antagonist
Hyponatremia is the most common electrolyte derangement 
occurring in hospitalized patients and is most oft en due 
to barorefl ex stimulation of antidiuretic hormone (ADH) 
secretion plus thirst induced by either volume depletion or 
abnormal cardiovascular function such as congestive heart 
failure. Tolvaptan, a novel,  orally active, selective, non-peptide 
antagonist that blocks arginine vasopressin from binding 
to V2 receptors of the distal nephron, induces the excretion 
of electrolyte-free water without changing the total level of 
electrolyte excretion. In patients with heart failure, tolvaptan 
appears to decrease body weight and edema and increase 
serum sodium concentrations without adversely aff ecting 
serum electrolyte levels, vital signs, or renal function. Schrier 
et al. now report the results of two randomized, placebo-
controlled, double-blind phase 3 studies (Study of Ascending 
Levels of Tolvaptan in Hyponatremia 1 and 2 (SALT-1 and 
SALT-2)) examining the eff ect of tolvaptan on hyponatremia 
of diverse causes. Th ese trials were designed to assess the 
outpatient use of tolvaptan for hyponatremia of diverse origin, 
including assessments of reversibility and safety.
Patients were randomly assigned to oral placebo (223 patients) 
or oral tolvaptan (225) at an initial dose of 15 mg daily. Th is 
dose was increased to 30 mg daily and then to 60 mg daily, if 
necessary, on the basis of serum sodium concentrations. Th e 
two primary end points for all patients were the change in 
the average daily area under the curve for the serum sodium 
concentration from baseline to day 4 and the change from 
baseline to day 30.
Th e results showed that serum sodium concentrations 
increased more in the tolvaptan group than in the placebo 
group both during the fi rst 4 days and aft er the full 30 days 
of therapy. During the week aft er discontinuation of tolvaptan 
on day 30, hyponatremia recurred. Side eff ects associated 
with tolvaptan included increased thirst, dry mouth, and 
increased urination. Th us, in patients with euvolemic or 
hypervolemic hyponatremia, tolvaptan, an oral vasopressin 
V2-receptor antagonist, was eff ective in increasing serum 
sodium concentrations.
Th ere appears to be little doubt that tolvaptan will be a 
welcome addition for the management of patients with 
inappropriate secretion of ADH (SIADH). Tolvaptan’s 
therapeutic effi  cacy may be less clear in conditions such as 
congestive heart failure or nephrotic syndrome in which ADH 
secretion (and increased thirst) is due to activation of the 
barorefl ex by a cardiovascular abnormality. Additional studies 
should answer these questions. (N Engl J Med 2006; 355: 
2099–2112)
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Albumin-induced survival or death 
of renal proximal tubule cells
Albuminuria is a well-known marker for renal disease, with a 
direct correlation with the progression of chronic kidney disease 
to end-stage renal disease. Serum albumin is retained in the 
bloodstream, because it does not readily cross the glomerular 
fi lter into the kidney. Th e fraction that is fi ltered is reabsorbed 
by proximal tubule cells by clathrin- and receptor-mediated 
endocytosis, which effi  ciently removes albumin from the 
fi ltrate. In many renal diseases, injury to the glomerulus breaks 
down the barrier function of the glomerulus, leading to excess 
fi ltration of albumin. Interestingly, long-term exposure of 
opossum kidney cells, a proximal tubule cell model, to high 
concentrations of albumin decreases albumin endocytosis, 
suggesting that high concentrations of albumin may be toxic to 
the cells. While renal proximal tubule cells have a remarkable 
ability to reabsorb large quantities of albumin through megalin-
mediated endocytosis, it is unclear why overstressing this 
endocytic system with a prolonged excess of albumin may injure 
the cells. Similarly, how proximal tubular cells function and 
protect themselves from injury during albumin reabsorption is 
unknown. Caruso-Neves et al. have recently shown that megalin 
is the sensor that determines whether cells will be protected 
or injured by albumin. Megalin, through a novel mechanism, 
binds phosphatidylinositol-3′-kinase/protein kinase B (PKB), 
anchoring this enzyme in the luminal plasma membrane. Low 
doses of albumin are protective, because they activate PKB, 
which promotes the phosphorylation and thus inactivation of 
proapototic proteins such as Bad, which belongs in the Bcl-2 
protein family. In contrast, an overload of albumin decreases 
megalin mRNA and protein expression, promotes the decrease 
in PKB in the luminal membrane, and decreases PKB activity. 
Th e drop in PKB activity ultimately leads to a reduction in Bad 
phosphorylation and consequently induces apoptosis in proximal 
tubule cells; the result is albumin-induced apoptosis. Th ese results 
reveal a model for PKB distribution in the plasma membrane 
and elucidate mechanisms involved in both the protective and 
the toxic eff ects of albumin on proximal tubule cells. In addition, 
the fi ndings suggest a novel mechanism for the progression of 
chronic kidney disease to end-stage renal disease and suggest 
that modulation of PKB activity by either variation of megalin 
expression or direct modulation by a ligand binding to a receptor 
could be a therapy in the evolution and progression of renal 
diseases. (Proc Natl Acad Sci USA 2006; 103: 18810–18815)
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Vitamin D receptor in bone 
regulates osteoclastogenesis, 
FGF23 production, and phosphate 
homeostasis
Vitamin D is the major regulator of calcium homeostasis and 
protects the organism from calcium defi ciency via eff ects on 
the intestine, kidney, and bone. Vitamin D interacts with the 
vitamin D receptor (VDR), a transcription factor regulating 
gene expression in several cell types, including osteoblasts and 
chondrocytes. Disorders of the vitamin D endocrine system 
by mutations in or inactivation of the VDR result in profound 
disturbances of mineral homeostasis (hypocalcemia and 
hyperparathyroidism) and of bone mineralization. A crucial 
mechanism contributing to this phenotype is a decrease in 
intestinal calcium absorption. During loss of VDR function, 
calcium supplementation corrects the hypocalcemia and 
hyperparathyroidism and restores bone mineralization, raising 
the question of the role of VDR in bone metabolism. It is, 
however, unknown whether VDR may play a specifi c, although 
not essential, role in bone.
Besides its role in calcium homeostasis, vitamin D also 
aff ects phosphate homeostasis by participating in a negative-
feedback loop with fi broblast growth factor-23 (FGF23). Th e 
phosphaturic factor FGF23 is produced mainly by bone and 
induces renal phosphate wasting by suppressing renal tubular 
sodium phosphate cotransporter type IIa (NPT2a) expression. 
Vitamin D enhances the production of FGF23, and mice lacking 
VDR show decreased circulating FGF23 levels.
To elucidate the role of vitamin D action during endochondral 
bone development, Masuyama et al. generated mice lacking 
VDR specifi cally in chondrocytes. Chondrocyte development 
was not aff ected by the lack of VDR, but vascular invasion was 
impaired and osteoclast number reduced in juvenile mice, 
resulting in increased trabecular bone mass. In vitro experiments 
confi rmed that VDR signaling in chondrocytes directly 
regulated osteoclastogenesis by inducing receptor activator of 
NF-κB ligand expression. Remarkably, mineral homeostasis was 
also aff ected in chondrocyte-specifi c VDR-null mice, as serum 
phosphate and 1,25(OH)2D levels were increased in young 
mice. Th e most surprising fi nding was that VDR inactivation in 
chondrocytes reduced the expression of FGF23 by osteoblasts 
and consequently led to increased renal expression of 1α-
hydroxylase and of sodium phosphate cotransporter type 
IIa. Taken together, these data reveal a novel role for VDR in 
chondrocytes as regulators of osteoclastogenesis and controllers 
of phosphate homeostasis, which they achieve by aff ecting 
FGF23 production. (J Clin Invest 2006; 116: 3150–3159)
Robert Safi rstein
Albumin modulates PKB in the plasma membrane of LL-CPK cells. White 
arrow, overlay of PKB and megalin. 20 = 20mg/ml)
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